Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer.

Author: Na WANG ^{1
,

2} ; Lu ZHAO ^{1
,

2} ; Dou ZHANG ^{1
,

2} ; Yingjie JIA ^{1
,

2} ; Fanming KONG ^{1
,

2}
Author Information

1. Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
2. National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China.
Publication Type:Journal Article
Keywords: Antibody-drug conjugates; Human epidermal growth factor receptor 2; Lung neoplasms
MeSH: Antibodies, Monoclonal/therapeutic use*; Antineoplastic Agents/therapeutic use*; Carcinoma, Non-Small-Cell Lung/drug therapy*; Humans; Immunoconjugates/therapeutic use*; Lung Neoplasms/drug therapy*
From: Chinese Journal of Lung Cancer 2022;25(3):214-218
CountryChina
Language:Chinese
Abstract: Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antibody-drug conjugates (ADCs) are the kind of potentially new anti-tumor drugs, consisting of monoclonal antibodies conjugated to the cytotoxic payloads via the synthetic linkers. They have a broad application prospect in solid tumors such as lung cancer. This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC. .